These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 10376979)

  • 1. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate.
    Qiu L; Kelso MJ; Hansen C; West ML; Fairlie DP; Parsons PG
    Br J Cancer; 1999 Jun; 80(8):1252-8. PubMed ID: 10376979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.
    Yelton CJ; Ray SK
    Neuroimmunol Neuroinflamm; 2018; 5():. PubMed ID: 30701185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in the delivery of epigenetic drugs.
    Cramer SA; Adjei IM; Labhasetwar V
    Expert Opin Drug Deliv; 2015; 12(9):1501-12. PubMed ID: 25739728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered histone modifications in gliomas.
    Kim YZ
    Brain Tumor Res Treat; 2014 Apr; 2(1):7-21. PubMed ID: 24926467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.
    Chueh AC; Tse JW; Tögel L; Mariadason JM
    Antioxid Redox Signal; 2015 Jul; 23(1):66-84. PubMed ID: 24512308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer.
    Min KN; Joung KE; Kim DK; Sheen YY
    Biomol Ther (Seoul); 2012 May; 20(3):313-9. PubMed ID: 24130929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells.
    Purrucker JC; Mahlknecht U
    Clin Epigenetics; 2010 Sep; 1(1-2):45-54. PubMed ID: 22704088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Cancer Effect of 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide in MCF-7 Human Breast Cancer.
    Min KN; Joung KE; Kim DK; Sheen YY
    Environ Health Toxicol; 2012; 27():e2012010. PubMed ID: 22639737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
    Wagner JM; Hackanson B; Lübbert M; Jung M
    Clin Epigenetics; 2010 Dec; 1(3-4):117-136. PubMed ID: 21258646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
    Brazelle W; Kreahling JM; Gemmer J; Ma Y; Cress WD; Haura E; Altiok S
    PLoS One; 2010 Dec; 5(12):e14335. PubMed ID: 21179472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
    Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.
    Sharma P; Kumar S; Kundu GC
    Mol Cancer; 2010 Jul; 9():178. PubMed ID: 20609221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase.
    Fayyad-Kazan H; Rouas R; Merimi M; El Zein N; Lewalle P; Jebbawi F; Mourtada M; Badran H; Ezzeddine M; Salaun B; Romero P; Burny A; Martiat P; Badran B
    J Biol Chem; 2010 Jul; 285(27):20481-91. PubMed ID: 20427269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epigenetics and genetics in neuro-oncology.
    Nagarajan RP; Costello JF
    Neurotherapeutics; 2009 Jul; 6(3):436-46. PubMed ID: 19560734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
    Gojo I; Jiemjit A; Trepel JB; Sparreboom A; Figg WD; Rollins S; Tidwell ML; Greer J; Chung EJ; Lee MJ; Gore SD; Sausville EA; Zwiebel J; Karp JE
    Blood; 2007 Apr; 109(7):2781-90. PubMed ID: 17179232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
    Ungerstedt JS; Sowa Y; Xu WS; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):673-8. PubMed ID: 15637150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
    Gui CY; Ngo L; Xu WS; Richon VM; Marks PA
    Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1241-6. PubMed ID: 14734806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses.
    Moreira JM; Scheipers P; Sørensen P
    BMC Cancer; 2003 Nov; 3():30. PubMed ID: 14606959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.
    Butler LM; Zhou X; Xu WS; Scher HI; Rifkind RA; Marks PA; Richon VM
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11700-5. PubMed ID: 12189205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
    Qiu L; Burgess A; Fairlie DP; Leonard H; Parsons PG; Gabrielli BG
    Mol Biol Cell; 2000 Jun; 11(6):2069-83. PubMed ID: 10848630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.